Literature DB >> 8550812

T cell antigenic and neuritogenic activity of recombinant human peripheral myelin P2 protein.

A Weishaupt1, G Giegerich, S Jung, R Gold, U Enders, M Pette, K Hayasaka, H P Hartung, K V Toyka.   

Abstract

The major neuritogenic protein of peripheral nerve myelin is the P2 protein. Human P2 is a candidate autoantigen in inflammatory demyelinating diseases of the peripheral nervous system. Since human P2 is not readily available, we produced full-length recombinant human P2 protein (rhP2) in Escherichia coli. RhP2 was recognized by neuritogenic rat T cell lines and induced experimental autoimmune neuritis in Lewis rats. Production of rhP2 allowed the generation of human T cell lines reactive to the autologous protein. Studies of human T cell autoreactivity as well as efforts to use hP2 as a tolerogen will be facilitated by the large-scale expression of rhP2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8550812     DOI: 10.1016/0165-5728(95)00139-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

1.  Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope.

Authors:  M Stienekemeier; K Falk; O Rötzschke; A Weishaupt; C Schneider; K V Toyka; R Gold; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance.

Authors:  C D Schmid; M Stienekemeier; S Oehen; F Bootz; J Zielasek; R Gold; K V Toyka; M Schachner; R Martini
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 3.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2.

Authors:  A Weishaupt; R Gold; S Gaupp; G Giegerich; H P Hartung; K V Toyka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.